Related references
Note: Only part of the references are listed.Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma
Barak Pertzov et al.
JOURNAL OF ASTHMA (2021)
The Prevalence of Subtypes of Type 2 Inflammation in an Unselected Population of Patients with Severe Asthma
Laurits Frossing et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)
Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
Arian Ghassemian et al.
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY (2021)
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma
Ioana Agache et al.
ALLERGY (2020)
Mepolizumab effectiveness and identification of super-responders in severe asthma
Erin S. Harvey et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Real-World Effectiveness and the Characteristics of a Super-Responder to Mepolizumab in Severe Eosinophilic Asthma
Joanne E. Kavanagh et al.
CHEST (2020)
Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype
Corrado Pelaia et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2020)
Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme
Camille Taille et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Bronchial thermoplasty versus mepolizumab: Comparison of outcomes in a severe asthma clinic
David Langton et al.
RESPIROLOGY (2020)
Treatment Eligibility of Real-Life Mepolizumab-Treated Severe Asthma Patients
Levi B. Richards et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)
Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs
Jean-Pierre Llanos et al.
JOURNAL OF ASTHMA AND ALLERGY (2020)
Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison
William Busse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Mepolizumab improves small airway function in severe eosinophilic asthma
Claude S. Farah et al.
RESPIRATORY MEDICINE (2019)
One year of mepolizumab. Efficacy and safety in real-life in Italy
Diego Bagnasco et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2019)
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response
Marco Caminati et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2019)
Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range
Dehui Luo et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2018)
Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response
Nora Drick et al.
BMC PULMONARY MEDICINE (2018)
Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study
Corrado Pelaia et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2018)
Randomised controlled trials in severe asthma: selection by phenotype or stereotype
Thomas Brown et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis
Daniel P. Henriksen et al.
EUROPEAN CLINICAL RESPIRATORY JOURNAL (2018)
Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials
Y. Cabon et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2017)
Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
Steven W. Yancey et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Biomarkers for severe eosinophilic asthma
Steven W. Yancey et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
Geoffrey L. Chupp et al.
LANCET RESPIRATORY MEDICINE (2017)
Real-life Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis
Abdulaziz Alhossan et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2017)
Biologic Therapy and Novel Molecular Targets of Severe Asthma
Amber N. Pepper et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2017)
'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review
I. Abraham et al.
ALLERGY (2016)
Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study
Njira Lugogo et al.
CLINICAL THERAPEUTICS (2016)
Mepolizumab versus placebo for asthma
Colin Powell et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2015)
Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
Xiang Wan et al.
BMC MEDICAL RESEARCH METHODOLOGY (2014)
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Kian Fan Chung et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Elisabeth H. Bel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector G. Ortega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Ian D. Pavord et al.
LANCET (2012)
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Pranabashis Haldar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Measurement properties and interpretation of three shortened versions of the asthma control questionnaire
EF Juniper et al.
RESPIRATORY MEDICINE (2005)
A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up
BT Kitch et al.
CHEST (2004)
Development of the asthma control test: A survey for assessing asthma control
RA Nathan et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Meta-analysis of observational studies in epidemiology - A proposal for reporting
DF Stroup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)